Evidence map›Paper›PMID 41602363›Full record

ArticleFrontiers in oncology2025

Global consensus for the screening, diagnosis, staging, treatment, and surveillance of ovarian cancer in areas of significant resource limitations: report from the International Gynecological Cancer Society consensus meeting.

Fernando Maluf, Henrique A Helber, Francinne Tostes, Ligia A Maluf, Juliana K Helito, Renato Moretti-Marques, Graziela Z Dal Molin, Bruno Roberto B Azevedo, David I Ortiz, David Cantu and 27 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Fernando MalufHospital Israelita Albert Einstein, São Paulo, Brazil.
Henrique A HelberHospital Israelita Albert Einstein, São Paulo, Brazil.
Francinne TostesHospital Israelita Albert Einstein, São Paulo, Brazil.
Ligia A MalufHospital Israelita Albert Einstein, São Paulo, Brazil.
Juliana K HelitoHospital Israelita Albert Einstein, São Paulo, Brazil.
Renato Moretti-MarquesHospital Israelita Albert Einstein, São Paulo, Brazil.
Graziela Z Dal MolinBeneficencia Portuguesa de Sao Paulo, São Paulo, Brazil.
Bruno Roberto B AzevedoOncoclinicas do Brasil, São Paulo, Brazil.
David I OrtizSociedad Medica del Instituto Nacional de Cancerologia, Mexico City, Mexico.
David CantuSociedad Medica del Instituto Nacional de Cancerologia, Mexico City, Mexico.
Agnaldo L Silva FilhoUniversidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Angelica Nogueira-RodriguesUniversidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Reitan RibeiroMcGill University, Montreal, QC, Canada.
Georgia F CintraInstituto Brasileiro de Controle do Cancer, São Paulo, Brazil.
Gustavo GuitmannInstituto Nacional de Cancer, Rio de Janeiro, Brazil.
Andreia Cristina de MeloInstituto Nacional de Cancer, Rio de Janeiro, Brazil.
Eduardo PaulinoInstituto Nacional de Cancer, Rio de Janeiro, Brazil.
Glauco BaiocchiA C Camargo Cancer Center, São Paulo, Brazil.
Leandro ResendeOncoclinicas do Brasil, São Paulo, Brazil.
Michelle S de AlmeidaHospital do Coracao, São Paulo, Brazil.
Diocesio A de AndradeOncoclinicas do Brasil, São Paulo, Brazil.
Julio L de la VegaGynecare Womens Health Clinic, Guatemala City, Guatemala.
Florencia NollSanatorio Allende Ginecologia y Obstetricia, Córdoba, Argentina.
Fabio FinCentro de Oncologia do Parana Ltda, Curitiba, Brazil.
Andre LopesA C Camargo Cancer Center, São Paulo, Brazil.
Miguel E CorreaOnco Prevee, Lima, Peru.
Joseph S NgNational University Cancer Institute, Singapore, Singapore.
Daniel SanabriaFundacion Universitaria de Ciencias de la Salud, Bogotá, Colombia.
Gabriel RendonInstituto de Cancerologia, Medellín, Colombia.
Fernando HerediaInstituto Oncologico Fundacion Arturo Lopez Perez, Providencia, Chile.
Ana Paula E LopesSultan Qaboos Comprehensive Cancer Care & Research Center, Muscat, Oman.
Myriam B MussiHospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Marcin BobinskiIndependent Translational Medicine Laboratory, Department of Medical Genetics, Medical University in Lublin, Lublin, Poland.
Milagros P QuintanillaAsociacion Medica del Centro Medico ABC, Mexico City, Mexico.
Jimena MeymarKenes Israel, Lod, Israel.
David AtallahHôtel Dieu de France, Saint Joseph University, Beirut, Lebanon.
Audrey TsunodaHCor, Ecomedical Center, Hospital Erasto Gaertner, PUCPR, Curitiba, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The objective of this consensus report is to provide practical, resource-stratified recommendations for the management of ovarian cancer in countries with limited resources, where direct application of international guidelines is often difficult. To address these challenges, recommendations were developed from a panel of international experts. Methods: The panel met in New York in September/October 2022 during the International Gynecological Cancer Society congress and was composed of specialists from countries in Africa, Asia, Eastern Europe, Latin America, and the Middle East. The panel addressed 72 questions and provided recommendations for the diagnosis, staging, treatment, and surveillance of ovarian cancer. Consensus was defined as at least 75% of the voting members selecting a particular recommendation, whereas a majority vote was considered when one option garnered between 50% and 74.9% of votes. Resource limitation was defined as any issues limiting access to qualified surgeons, contemporary imaging or radiation-oncology techniques, antineoplastic drugs, or funding for providing modern medical care. Results: Consensus was reached for 10 out of 72 (13.9%) questions presented to the panel, whereas a majority vote was reached for 26 (36.1%) additional questions. For the remaining questions, there was considerable heterogeneity in the recommendations. Conclusion: The development of guidelines focusing on areas facing more severe resource limitations may improve medical practice and patient care.

Indexed as

consensus statementglobal healthlow- and middle-income countriesovarian cancerresource-stratified guidelines

Identifiers

PMID41602363
PMCPMC12833755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.